EA035519B9 - 1,3,4-тиадиазольные соединения и их применение в лечении рака - Google Patents
1,3,4-тиадиазольные соединения и их применение в лечении ракаInfo
- Publication number
- EA035519B9 EA035519B9 EA201891239A EA201891239A EA035519B9 EA 035519 B9 EA035519 B9 EA 035519B9 EA 201891239 A EA201891239 A EA 201891239A EA 201891239 A EA201891239 A EA 201891239A EA 035519 B9 EA035519 B9 EA 035519B9
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- pharmaceutically acceptable
- treating cancer
- gls1
- compound
- acceptable salt
- Prior art date
Links
- 150000004869 1,3,4-thiadiazoles Chemical class 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 101710184006 Glutaminase 1 Proteins 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562260784P | 2015-11-30 | 2015-11-30 | |
| PCT/EP2016/079253 WO2017093301A1 (en) | 2015-11-30 | 2016-11-30 | 1,3,4-thiadiazole compounds and their use in treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EA201891239A1 EA201891239A1 (ru) | 2018-11-30 |
| EA035519B1 EA035519B1 (ru) | 2020-06-29 |
| EA035519B9 true EA035519B9 (ru) | 2020-08-10 |
Family
ID=57460503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201891239A EA035519B9 (ru) | 2015-11-30 | 2016-11-30 | 1,3,4-тиадиазольные соединения и их применение в лечении рака |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US10040789B2 (enExample) |
| EP (1) | EP3383872B1 (enExample) |
| JP (1) | JP6821680B2 (enExample) |
| KR (1) | KR20180083411A (enExample) |
| CN (1) | CN108349965B (enExample) |
| AR (1) | AR106875A1 (enExample) |
| AU (1) | AU2016361834B2 (enExample) |
| BR (1) | BR112018008330B1 (enExample) |
| CA (1) | CA3005517C (enExample) |
| CL (1) | CL2018001409A1 (enExample) |
| CO (1) | CO2018006930A2 (enExample) |
| DK (1) | DK3383872T3 (enExample) |
| DO (1) | DOP2018000135A (enExample) |
| EA (1) | EA035519B9 (enExample) |
| ES (1) | ES2796562T3 (enExample) |
| IL (1) | IL259508A (enExample) |
| MX (1) | MX2018006483A (enExample) |
| MY (1) | MY195680A (enExample) |
| NI (1) | NI201800063A (enExample) |
| NZ (1) | NZ743699A (enExample) |
| PE (1) | PE20181522A1 (enExample) |
| PH (1) | PH12018501133A1 (enExample) |
| SG (1) | SG11201803808VA (enExample) |
| SV (1) | SV2018005700A (enExample) |
| TN (1) | TN2018000118A1 (enExample) |
| TW (1) | TW201731511A (enExample) |
| WO (1) | WO2017093301A1 (enExample) |
| ZA (1) | ZA201804361B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201520959D0 (en) | 2015-11-27 | 2016-01-13 | Astrazeneca Ab And Cancer Res Technology Ltd | Bis-pyridazine compounds and their use in treating cancer |
| US9938265B2 (en) | 2015-11-30 | 2018-04-10 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| US10323028B2 (en) | 2015-11-30 | 2019-06-18 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| CN112888686B (zh) * | 2018-10-16 | 2022-04-19 | 南京明德新药研发有限公司 | 噻二唑衍生物及其作为gls1抑制剂的应用 |
| CN114560855B (zh) * | 2021-03-26 | 2023-05-23 | 成都苑东生物制药股份有限公司 | 环烷基甲酰胺类衍生物、其制备方法及用途 |
| WO2025196446A1 (en) | 2024-03-22 | 2025-09-25 | Sitryx Therapeutics Limited | Thiadiazoles as glutaminase 1 inhibitors |
| WO2025196447A1 (en) | 2024-03-22 | 2025-09-25 | Sitryx Therapeutics Limited | Thiadiazoles as glutaminase 1 inhibitors |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013078123A1 (en) * | 2011-11-21 | 2013-05-30 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
| US20140142081A1 (en) * | 2012-11-22 | 2014-05-22 | Agios Pharmaceuticals, Inc | Compounds and their methods of use |
| WO2015181539A1 (en) * | 2014-05-30 | 2015-12-03 | Astrazeneca Ab | 1, 3, 4-thiadiazole compounds and their use in treating cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014079011A1 (en) * | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
| EP3092235A2 (en) | 2014-01-06 | 2016-11-16 | Rhizen Pharmaceuticals S.A. | Novel inhibitors of glutaminase |
| US9938265B2 (en) * | 2015-11-30 | 2018-04-10 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| US10323028B2 (en) * | 2015-11-30 | 2019-06-18 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
-
2016
- 2016-11-29 US US15/362,989 patent/US10040789B2/en active Active
- 2016-11-29 TW TW105139334A patent/TW201731511A/zh unknown
- 2016-11-30 MY MYPI2018702070A patent/MY195680A/en unknown
- 2016-11-30 JP JP2018527201A patent/JP6821680B2/ja active Active
- 2016-11-30 AU AU2016361834A patent/AU2016361834B2/en active Active
- 2016-11-30 NZ NZ743699A patent/NZ743699A/en unknown
- 2016-11-30 SG SG11201803808VA patent/SG11201803808VA/en unknown
- 2016-11-30 ES ES16805078T patent/ES2796562T3/es active Active
- 2016-11-30 PE PE2018001012A patent/PE20181522A1/es unknown
- 2016-11-30 CA CA3005517A patent/CA3005517C/en active Active
- 2016-11-30 MX MX2018006483A patent/MX2018006483A/es unknown
- 2016-11-30 EP EP16805078.9A patent/EP3383872B1/en active Active
- 2016-11-30 TN TNP/2018/000118A patent/TN2018000118A1/en unknown
- 2016-11-30 EA EA201891239A patent/EA035519B9/ru not_active IP Right Cessation
- 2016-11-30 DK DK16805078.9T patent/DK3383872T3/da active
- 2016-11-30 KR KR1020187017163A patent/KR20180083411A/ko not_active Withdrawn
- 2016-11-30 BR BR112018008330-5A patent/BR112018008330B1/pt active IP Right Grant
- 2016-11-30 CN CN201680067210.XA patent/CN108349965B/zh active Active
- 2016-11-30 AR ARP160103664A patent/AR106875A1/es unknown
- 2016-11-30 WO PCT/EP2016/079253 patent/WO2017093301A1/en not_active Ceased
-
2018
- 2018-05-22 IL IL259508A patent/IL259508A/en active IP Right Grant
- 2018-05-24 CL CL2018001409A patent/CL2018001409A1/es unknown
- 2018-05-29 NI NI201800063A patent/NI201800063A/es unknown
- 2018-05-29 PH PH12018501133A patent/PH12018501133A1/en unknown
- 2018-05-29 SV SV2018005700A patent/SV2018005700A/es unknown
- 2018-05-29 DO DO2018000135A patent/DOP2018000135A/es unknown
- 2018-06-28 ZA ZA2018/04361A patent/ZA201804361B/en unknown
- 2018-06-29 CO CONC2018/0006930A patent/CO2018006930A2/es unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013078123A1 (en) * | 2011-11-21 | 2013-05-30 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
| US20140142081A1 (en) * | 2012-11-22 | 2014-05-22 | Agios Pharmaceuticals, Inc | Compounds and their methods of use |
| WO2015181539A1 (en) * | 2014-05-30 | 2015-12-03 | Astrazeneca Ab | 1, 3, 4-thiadiazole compounds and their use in treating cancer |
Non-Patent Citations (1)
| Title |
|---|
| AJIT G. THOMAS, CLIONA M. O’DRISCOLL, JOSEPH BRESSLER, WALTER E. KAUFMANN, CAMILO J. ROJAS, BARBARA S. SLUSHER: "Small molecule glutaminase inhibitors block glutamate release from stimulated microglia", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS, vol. 443, no. 1, 1 January 2014 (2014-01-01), pages 32 - 36, XP055200049, ISSN: 0006291X, DOI: 10.1016/j.bbrc.2013.11.043 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019500395A1 (en) | Amino-pyrrolopyrimidinone compounds and methods of use thereof | |
| EA035519B9 (ru) | 1,3,4-тиадиазольные соединения и их применение в лечении рака | |
| PH12019500214A1 (en) | Substituted thiazolo-pyridine compounds as malt1 inhibitors | |
| MX395482B (es) | Compuestos antiproliferativos y metodos de uso de los mismos | |
| NZ739503A (en) | A novel approach for treatment of cancer using immunomodulation | |
| MY196576A (en) | Amino Pyrimidine SSAO Inhibitors | |
| SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
| MY201629A (en) | Benzopyrazole compounds and analogues thereof | |
| EA201692079A1 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
| NZ724250A (en) | Human plasma kallikrein inhibitors | |
| PH12017500493A1 (en) | Combination therapy | |
| PH12016502354A1 (en) | Pharmaceutical composition | |
| EA201891063A1 (ru) | Производные дигидроимидазопиразинона, применимые в лечении рака | |
| MX2017001620A (es) | Formas cristalinas de inhibidores de glutaminasa. | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| PH12016502353A1 (en) | Pharmaceutical composition | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| PH12020550462A1 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
| WO2016004404A3 (en) | Gls1 inhibitors for treating disease | |
| MX381440B (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| MX2021010297A (es) | Inhibidores de calicreina plasmatica humana. | |
| WO2016004413A3 (en) | Gls1 inhibitors for treating disease | |
| MX2017000208A (es) | Derivados de quinolizinona como inhibidores de pi3k. | |
| MX2019004822A (es) | Derivado del pirazol 3,4-bipiridilo y metodo de preparacion del mismo y aplicacion medica del mismo. | |
| EA201792265A1 (ru) | Способы лечения сердечно-сосудистых заболеваний |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH4A | Publication of the corrected specification to eurasian patent | ||
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |